Pramlintide is a copy of amylin. CagriSema is a cagrilintide + semaglutide blend.
Amylin is the fullness hormone your pancreas releases alongside insulin.
The difference is reach: Pramlintide acts on 1 receptor and CagriSema acts on 2 receptors. More receptors has generally meant more effect, and more side effects.
| Comparison | Pramlintide Symlin | CagriSema cagrilintide and semaglutide |
|---|---|---|
| How it works | How it works Pramlintide copies amylin, and it was the first drug in this family, approved back in 2005 for use alongside insulin rather than for weight loss. | How it works CagriSema is two drugs in one weekly injection: cagrilintide and semaglutide, at fixed doses. The logic is that two separate fullness pathways should add up. |
| What it is | An approved mealtime shot used with insulin to blunt blood-sugar spikes and hunger. | A weekly two-in-one shot combining cagrilintide and semaglutide for bigger loss. |
| Status | FDA approvedFDA-approved | In trialsInvestigational |
| Typical dose | 0.015–0.12 mg per dose | 2.4 mg per week |
| How often | With meals | Weekly |
| Stays active | ~48 minutes | Not established |
| Dose comes from | FDA drug label | Clinical trial protocol |
| Cycled? | Not cycled FDA drug label | Not cycled in the trials Clinical trial protocol |
| What it does | ||
| Drug class | Amylin analog | Cagrilintide + semaglutide blend |
| Used for | An approved mealtime shot used with insulin in diabetes. It blunts the blood-sugar spike after eating and reduces hunger. | A weekly two-in-one shot combining an appetite-lowering peptide with semaglutide, for bigger weight loss than either alone. |
| Receptors hit | amylin | GLP-1, amylin |
| Numbers | ||
| Full dose line | 0.015 up to 0.12 mg per dose (start low, increase slowly) | 2.4 mg per week |
| Why that cycle | Taken continuously for as long as it is working. Neither the label nor clinical practice describes an on/off schedule. | Given continuously for the whole study period: REDEFINE 1, 68 weeks. The dose is stepped up at the start, which is a ramp rather than a cycle, and no trial in this class built in a planned break. |
| Weight / effect | Not measured in a trial | Not measured in a trial |
| Chain length | 37 residues | Not disclosed |
| Common vial | 5 mg | 10 mg |
| Before you start | ||
| Route | Under the skin (subcutaneous) | Under the skin (subcutaneous) |
| Do not use if | Not being able to feel low blood sugar coming on (hypoglycemia unawareness) Severe stomach-emptying problems (gastroparesis) Pregnancy | A personal or family history of medullary thyroid cancer, or MEN 2 Pregnancy |
What separates them
Proof behind the dose. Pramlintide has a dose taken straight off an FDA drug label. CagriSema has a dose from a clinical trial protocol.
What doesn't differ: They are both taken the same way (under the skin). Neither has a measured effect size from a published trial, so there is no number to rank them on.
What people actually report
Pramlintide
- It can cause low blood sugar when used with insulin, plus nausea.
- Signs of severe low blood sugar such as confusion, shaking, sweating, or fainting, which is the boxed warning on this drug
- Severe or persistent vomiting
CagriSema
- Stomach side effects.
- The dose is increased slowly from a low start, and it is not yet approved.
- Severe stomach pain that spreads to your back
- A lump or swelling in your neck, hoarseness, or trouble swallowing
Side effects are what users and trials report most often, not a complete list. Anything sudden, spreading, or breathing-related is an emergency regardless of which compound caused it.
People also compare
This comparison does not cover cost, long-term safety, or how you personally will respond. Effect figures come from separate trials in different populations and are not always directly comparable to each other. Nothing here is medical advice or a recommendation to use any of these. Talk to a clinician about your own situation.